Command Palette

Search for a command to run...

oxygenta-pharmaceutical

55.76-4.99%
Market Cap
₹0.00 Cr
Stock P/E
0.00
ROCE
0.00%
ROE
0.00%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Laggard

Oxygenta Pharmaceutical Ltd. stands out as a sector laggard, exhibiting negative financial metrics across growth, profitability, and valuation, with no revenues or profits, while peers demonstrate diverse strengths. Companies like Sun Pharmaceutical and Dr. Reddy's Laboratories show strong profitability and growth, contrasting sharply with Oxygenta's performance.

Key Points
  • Oxygenta has negative PE and PBV ratios, indicating deep financial distress.
  • Sun Pharmaceutical leads in growth metrics with a 8.42% YoY revenue increase and a healthy EPS of 45.55.
  • Dr. Reddy's and Cipla are strong performers in profitability with ROE above 21%.
Top Performers
Sun Pharmaceutical Industries Ltd.

Highest revenue growth YoY (8.42%) and strong EPS (45.55) with a solid ROE (16.13%).

Dr. Reddy's Laboratories Ltd.

High profitability with an ROE of 21.76% and consistent revenue growth.

Cipla Ltd.

Strong growth trajectory with a YoY revenue increase of 13.28% and a competitive ROE of 16.63%.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.